

Special Issue

Glycometabolic Control in Older Patients with Type 2 Diabetes

Message from the Guest Editor

Type 2 diabetes mellitus (T2DM) is a chronic condition with an increasing prevalence worldwide, especially in the older population. T2DM leads to micro- and microvascular complications, cognitive impairment, and risk of falls, fractures, and frailty. The ideal management of T2DM therapy in such a peculiar population could not disregard a broad evaluation of frailty, in order to set a glycemic target appropriate for the life expectancy and the reserve which the older patients present, as also underlined in the most recent guidelines. Incredibly interesting would then be a detailed discussion about what the new therapeutic targets should be, especially in view of the new therapeutic strategies brought forth by new available drugs with a wide spectrum of action. Interest should particularly be addressed to older patients, both in the acute care setting and in the chronic one, considering the interplay with frailty, chronic diseases such as cardiovascular and renal impairment, and polytherapy.

Guest Editor

Dr. Valeria Calsolaro

Geriatrics Unit, University of Pisa, Via Savi 10, 56126 Pisa, Italy

Deadline for manuscript submissions

closed (15 March 2023)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



mdpi.com/si/115056

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).